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the reimbursement institutions in Turkey has been reflected upon the costs. As a
value of effectiveness, the rate of completing the treatment has been chosen. The
success rate of completing the treatment determined as 2 doses and 3 doses per
day has been gathered from the literature. The completion level of the treatment
for 2 doses per day is 68% and for the agents used for 3 doses, it is 50%. RESULTS: In
terms of incremental cost per additional completing doses, amoxicillin clavulanate
is cost saving versus amoxicillin group for the treatment of community acquired
pneumonia (-113.43 TL), acute rhinosinusitis (-70.73 TL), acute otitis media (-70.73
TL), tonsillopharyngitis (-52.06 TL). CONCLUSIONS: According to the results de-
rived from the comparison between the costs and effectiveness values; for the each
illness at primary care, the use of amoxicillin clavulanate is cost saving in order to
complete the treatment successfully.
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OBJECTIVES: HPV vaccination of young girls is a preventive strategy now recom-
mended in most industrialised countries. As HPV can cause cancers and diseases in
both sexes, questions are raised about the health and economic impact of extend-
ing HPV vaccination programme to boys. The aim of this study was to review the
cost-effectiveness studies of boys HPV vaccination and provide recommendations
for future research. METHODS: Cost-effectiveness models of HPV vaccination that
consider boys vaccination as a possible vaccination strategy published before the
end of 2011 were included in the study. Models were compared from a number of
aspects, including modelling approach, model calibration, diseases modelled, HPV
transmission patterns, vaccination and screening strategies and input parameters
(transition probabilities, costs, effectiveness, discount rates). RESULTS: Six US and
three European studies were included in the review. Four in nine used a standard
dynamic model, and three different types of models were used in other studies.
Results differed widely according to HPV-related diseases considered: analyses
modelling cervical cancer only, with or without genital warts, yielded a higher
cost-effectiveness ratio. The comparator considered usually did not account for
vaccination strategies implemented. Results were very sensitive to country-spe-
cific parameters, such as the current vaccination coverage in girls (the most favour-
able cost-effectiveness ratios for boy vaccination were achieved when girls vacci-
nation coverage was low), vaccine price, vaccine characteristics and the
assumption on natural immunity of HPV. CONCLUSIONS: Few analyses examined
the cost-effectiveness of extending HPV vaccination to boys. As methods and pa-
rameters differed across studies, the review provided limited conclusions. The
cost-effectiveness of a girls and boys vaccination programme should include all
benefits expected from HPV vaccination and should be evaluated on a country-by-
country basis to take into account local specificities, such as observed coverage rate
in girls and vaccine price.
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OBJECTIVES: Chronic hepatitis C genotype 1 (HCV) may lead to cirrhosis, liver
cancer, liver transplant, increased mortality. Peginterferon-alpha and ribavirin (PR)
results in complete cure (Sustained Viral Response) in less than 50% of patients.
Aim of this study was to assess the cost-utility of telaprevirPR (TPR) compared to
boceprevirPR (BPR) and PR alone in the management of HCV in adults with mild,
moderate HCV, compensated liver disease, including cirrhosis, who have not been
treated before or have been treated with PR but failed treatment. METHODS: A
Markov model with a lifelong time horizon using annual cycles was developed to
compare TPR, BPR and PR in treatment-naïve patients (TN) and treatment-experi-
enced patients (TE). Clinical data were provided by published phase 3 trials (TPR vs.
PR, BPR vs. PR) and a mixed treatment comparison for the indirect comparison TPR
vs. BPR. Dutch unit costs (direct and indirect) and utilities were taken from a Dutch
observational study in HCV patients. Annual discounting of 4% and 1.5% was ap-
plied on costs and outcomes respectively. The cost per quality-adjusted life-year
(QALY) was calculated from the societal perspective using the Human Capital
Approach. RESULTS: Treating TN with TPR generates 0.85 QALYs gained and €634
additional cost compared to PR, resulting in an incremental cost-utility ratio (ICUR)
of €746/QALY. In TE, TPR dominates PR with cost–savings (-€6,621) and 1.78 addi-
tional QALYs. Also, TPR dominates BPR with higher effects (0.20 in TN; 0.79 in TE)
and cost-savings (-€7,224 in TN; -€22,110 in TE). Sensitivity analysis showed that
time horizon affected the ICERs. The probability to obtain an ICER20,000€/QALY is
100% (probabilistic sensitivity analysis). CONCLUSIONS: Based on the results of
this local adaptation, TPR is highly cost effective versus PR alone in TN patients. It
was a dominant option in all other comparisons (including boceprevir and treat-
ment for TE patients).
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OBJECTIVES: Currently, 400-500 thousand people are suffering from Hepatitis C in
Germany (62% genotype 1). Treatment of genotype 1 chronic Hepatitis C has been
improved by recently approved new direct acting antivirals. Clinical studies
showed a significant increase in sustained virological response rates from 38-46%
to 63-79%. This study was to evaluate the cost-effectiveness of newly introduced
triple therapy with Telaprevir (TVRPR) compared to dual therapy (PR) for the
treatment of genotype 1 hepatitis C virus (HCV) infection in previously untreated
patients. METHODS: A previously published economic Markov model comparing
triple therapy (TVRPR) and dual therapy (PR) was adjusted for the German health
care context (payer perspective). Effectiveness was measured on the basis of qual-
ity adjusted life years (QALY). Clinical outcomes and drug dosage were taken from
the ADVANCE phase-3 trial. Other model parameters – including utilities - were
adapted from German or if not available from international literature after an
extensive literature search. Drug costs were taken from the German drug directory.
All costs were inflated to the year 2012. A discount rate of 3% and a lifetime horizon
were assumed. RESULTS: Base-case analysis shows that triple treatment (TVRPR)
compared with dual therapy (PR) results in higher costs (€49,378 vs. €30,743) and
better outcomes (16.7 vs. 15.8 QALYs). The incremental costs per QALY gained were
€21,277. Results were robust in multiple sensitivity analyses. Discount rate seemed
to have major impact: a discount rate of 0% results in an ICER of 7,381 €/QALY, a
discount rate of 5% in 34,694 €/QALY. CE acceptability curve shows a probability of
an ICER below 30,000 €/QALY of more than 90%. CONCLUSIONS: Triple therapy
with telaprevir for treatment-naïve HCV-genotype 1 patients is more effective than
dual therapy, but results in higher costs (notably drug costs).
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OBJECTIVES: Herpes Zoster (HZ) is a painful disease resulting from reactivation of
the varicella-zoster virus which can cause post-herpetic neuralgia (PHN), a debili-
tating pain persisting from three months to years after rash onset. The incidence
and severity associated with HZ negatively impacts functional status and quality of
life and increases with advancing age. A vaccine preventing HZ and PHN in people
aged 50 and more will soon be available in Europe. This study aimed to assess the
cost-effectiveness of zoster vaccination in France. METHODS: A published Markov
model was adapted to the French setting. Cost-effectiveness of vaccinating 20% of
individuals aged 70-79 was evaluated over lifetime from a national health care
perspective. Base case analysis considered French epidemiological, economic and
EQ-5D based utility data. The analysis assumed a waning vaccine efficacy of 4.15%
annually as suggested by clinical data. A discount of 4% was applied to costs and
outcomes over the first 30 years and a 2% rate thereafter. Extensive sensitivity
analyses were performed on factors of influence described in the literature.
RESULTS: Incremental cost-effectiveness ratios were estimated at 9,693€ per QALY
gained, 1,529€ per avoided HZ case and 3,480€ per avoided PHN case. The probabil-
ity that the ICERs were below €28,000 to €84,000/QALY (one to three times the GDP
per capita) were greater than 92% and 95%, respectively. Univariate sensitivity
analysis confirmed the favorable cost-effectiveness profile, ranging from 5,793 to
19,565€/QALY gained. Duration of protection and utility estimates were the most
impactful parameters. Vaccination policy targeting other cohorts, such as people
aged 65 years-old was also found cost-effective, with an ICER estimated at 7,217€/
QALY gained. CONCLUSIONS: Beyond epidemiological and clinical evidence,
health-economic evidence supports the implementation of a zoster vaccination
policy in the French senior population aged 70 and over.
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OBJECTIVES: Streptococcus pneumoniaeis a leading cause of life-threatening
pneumococcal disease. In the UK, PPV23 is recommended in the elderly (aged 65
and over) and at-risk adults. In 2007, PCV was introduced in children, leading to a
decrease in invasive pneumococcal disease (IPD) incidence associated with the PCV
serotypes not only in vaccinated children but also in unvaccinated adults. The use
of PCV13 in adults is currently under consideration pending data on efficacy in this
population. This study assessed the CE of PPV23 vs. PCV13 or NoVac in the UK,
accounting for epidemiological changes. METHODS: An existing population-based
Markov model was adapted to the UK. Five health states were considered: no IPD,
IPD, NBPP (non-bacteraemic pneumococcal pneumonia), post-meningitis sequelae
and death. Epidemiology and costs were estimated from UK sources. The analysis
tracked one cohort of individuals assuming PPV23, PCV13 or NoVac from 2012 until
death. Costs and QALYs were discounted at 3.5%. RESULTS: Over lifetime, vacci-
nating the cohort with PPV23 avoided 226 (vs. PCV13) to 337 (vs. NoVac) IPD cases.
Vaccinating with PPV23 resulted in an increment of 337 (vs. PCV13) to 631 (vs.
NoVac) QALYs. PPV23 was associated with savings of approximately £21 million vs.
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